Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen

SARS-CoV-2 3CL Protease is one of the key targets for drug development against COVID-19. Most known SARS-CoV-2 3CL Protease Inhibitors act by covalently binding to the active site cysteine. Yet, computational screens against this Enzyme were mainly focused on non-covalent inhibitor discovery. Here, we developed a deep learning-based stepwise strategy for selective covalent inhibitor screen. We used a deep learning framework that integrated a directed message passing neural network with a feed-forward neural network to construct two different classifiers for either covalent or non-covalent inhibition activity prediction. These two classifiers were trained on the covalent and non-covalent 3CL Protease Inhibitors dataset, respectively, which achieved high prediction accuracy. We then successively applied the covalent inhibitor model and the non-covalent inhibitor model to screen a chemical library containing compounds with covalent warheads of cysteine. We experimentally tested the inhibition activity of 32 top-ranking compounds and 12 of them were active, among which 6 showed IC₅₀ values less than 12 μM and the strongest one inhibited SARS-CoV-2 3CL Protease with an IC₅₀ of 1.4 μM. Further investigation demonstrated that 5 of the 6 active compounds showed typical covalent inhibition behavior with time-dependent activity. These new covalent inhibitors provide novel scaffolds for developing highly active SARS-CoV-2 3CL covalent inhibitors.

3C-like protease inhibitors; Covalent warheads; Deep learning; SARS-CoV-2.